| Literature DB >> 26682842 |
Chetan Videkar1, Aditya Kapoor1, Jay Chhablani2, Raja Narayanan1.
Abstract
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema. We report a case of PCV resistant to PDT and ranibizumab, which responded well to intravitreal ziv-aflibercept. 2015 BMJ Publishing Group Ltd.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26682842 PMCID： PMC4691871 DOI： 10.1136/bcr-2015-212988
Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X